|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0024934,
umls-concept:C0026336,
umls-concept:C0026339,
umls-concept:C0030193,
umls-concept:C0034693,
umls-concept:C0034721,
umls-concept:C0205099,
umls-concept:C0205100,
umls-concept:C0332307,
umls-concept:C0456603,
umls-concept:C0538927,
umls-concept:C0936012,
umls-concept:C1257954,
umls-concept:C1314939,
umls-concept:C1565860,
umls-concept:C1704711,
umls-concept:C1705323,
umls-concept:C2757001
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-12-6
|
|
pubmed:abstractText |
The purpose of this study is to clarify involvement ratios between central and peripheral cyclooxygenase (COX)-2 in rat inflammatory pain models, by evaluating celecoxib and [6-chloro-2-(4-chlorobenzoyl)-1H-indol-3-yl]acetic acid (CIAA) on carrageenan-induced mechanical and thermal hyperalgesia. Celecoxib and CIAA exhibited ID(30) values with 1.5 and 7.7 mg/kg on mechanical hyperalgesia, respectively, and ID(25) values with 0.54 and 36 mg/kg on thermal hyperalgesia, respectively. By solving quadratic functional analysis with prostaglandin E(2) (PGE(2)) inhibitory activities, it was calculated that involvement ratios between central and peripheral COX-2 involvement were 0.47 and 0.53 on mechanical hyperalgesia, and 0.97 and 0.03 on thermal hyperalgesia, respectively. These data suggest that central and peripheral COX-2 are equally involved in mechanical hyperalgesia, while central COX-2 is predominantly involved in thermal hyperalgesia.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0014-2999
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
6
|
|
pubmed:volume |
578
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
97-9
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:17716650-Animals,
pubmed-meshheading:17716650-Carrageenan,
pubmed-meshheading:17716650-Chlorobenzoates,
pubmed-meshheading:17716650-Cyclooxygenase 2,
pubmed-meshheading:17716650-Cyclooxygenase 2 Inhibitors,
pubmed-meshheading:17716650-Dinoprostone,
pubmed-meshheading:17716650-Disease Models, Animal,
pubmed-meshheading:17716650-Dose-Response Relationship, Drug,
pubmed-meshheading:17716650-Hot Temperature,
pubmed-meshheading:17716650-Hyperalgesia,
pubmed-meshheading:17716650-Indoleacetic Acids,
pubmed-meshheading:17716650-Inflammation,
pubmed-meshheading:17716650-Male,
pubmed-meshheading:17716650-Models, Biological,
pubmed-meshheading:17716650-Pain,
pubmed-meshheading:17716650-Pain Measurement,
pubmed-meshheading:17716650-Pyrazoles,
pubmed-meshheading:17716650-Rats,
pubmed-meshheading:17716650-Rats, Sprague-Dawley,
pubmed-meshheading:17716650-Sulfonamides,
pubmed-meshheading:17716650-Tissue Distribution
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA.
|
|
pubmed:affiliation |
Discovery Biology Research, Nagoya Laboratories, Pfizer Global Research and Development, Pfizer Inc., 5-2 Taketoyo, Aichi, 470-2393, Japan. Takako.Okumura@pfizer.com
|
|
pubmed:publicationType |
Journal Article
|
